Braftovi (encorafenib) — Medica
Colon or Rectal Cancer
Initial criteria
- age ≥ 18 years
- patient has BRAF V600E mutation-positive disease
- EITHER (a) the medication will be used as first-line systemic therapy for metastatic disease AND will be used in combination with Erbitux (cetuximab) or Vectibix (panitumumab) AND with FOLFOX (5-FU, leucovorin, and oxaliplatin)
- OR (b) patient has previously received a chemotherapy regimen for colon or rectal cancer AND the medication is used in combination with Erbitux or Vectibix
Approval duration
1 year